The Food and Drug Administration has cleared the NeuroStar transcranial magnetic stimulation system (TMS) from Neuronetics as an adjunct treatment of major depressive order in adolescents, the company recently announced.
In July 2022, the FDA cleared the system to treat anxious depression, expanding the clearance at that time from its previous clearance to treat obsessive-compulsive disorder
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?